Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760152 | 1.00 | BACE1 (0.37) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL10293166 | 1.00 | BACE1 (0.37) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL756887 | 1.00 | BACE1 (0.37) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL10293167 | 1.00 | BACE1 (0.37) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL14640804 | 1.00 | BACE1 (0.37) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL8247533 | 0.91 | BACE1 (0.40) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL758064 | 0.91 | BACE1 (0.40) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL5616293 | 0.89 | BACE1 (0.35) | BACE1BACE2 | |
| SCHEMBL5616430 | 0.89 | BACE1 (0.35) | BACE1BACE2 | |
| SCHEMBL756120 | 0.88 | PDK1 (0.38) | BACE1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211904-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1910364-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | BACE1, APP, PSEN1 | BACE1 1/4885PDK1 1880/4885PDK2 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.